- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- ROUNDTABLE: Pharmacy’s future in sync with technology
- Dr. Smith's Diaper Rash Ointment
- Cefaly makes Rx medical device for the preventive treatment of migraine headaches available online
- CVS Caremark to stop selling tobacco in all store locations
SCHOFIELD, Wis. — PuraMed BioScience on Monday announced that headache researcher Roger Cady will be exhibiting a poster presentation of his independent clinical study of PuraMed's nonprescription migraine medication LipiGesic-M at the 2011 Headache Update Conference being held in Orlando, Fla., July 14 to 17.
The study recently was published online in Headache, the medical journal of the American Headache Society, and is expected to be published in the printed version shortly.
"This will be a very important meeting for PuraMed BioScience because of the interest elicited by Dr. Cady's recently published independent clinical study of LipiGesic-M," stated PuraMed BioScience CEO Russell Mitchell. "This is an excellent opportunity for us to introduce and further discuss our product and study with many of the leading headache specialists in the [United States]."
The presentation by Cady will highlight the recent study that reported 64% of subjects found pain relief within two hours of taking LipiGesic-M. The study concluded that sublingual feverfew/ginger appears safe and effective as a first-line treatment for a population of migraine sufferers who frequently experience mild headache prior to the onset of moderate to severe headache.